900.1000 -39.90 (-4.24%)
NSE Jan 16, 2026 15:31 PM
Volume: 470.2K
 

900.10
-4.24%
Axis Direct
Regulated markets sales (78% of sales) grew 29% YoY/ 16% QoQ on strong growth in US (over 20% YoY) and steady growth in Australia (high single digit). However, Emerging markets sales (22% of sales) declined 39% YoY/ 38% QoQ due to API supply chain disruption, pricing issues in the ARV portfolio
Strides Pharma Science Ltd. is trading above its 200 day SMA of 833.9
More from Strides Pharma Science Ltd.
Recommended